ATE325341T1 - Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden - Google Patents

Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden

Info

Publication number
ATE325341T1
ATE325341T1 AT02760451T AT02760451T ATE325341T1 AT E325341 T1 ATE325341 T1 AT E325341T1 AT 02760451 T AT02760451 T AT 02760451T AT 02760451 T AT02760451 T AT 02760451T AT E325341 T1 ATE325341 T1 AT E325341T1
Authority
AT
Austria
Prior art keywords
bases
phosphodiesteroligonucleotides
apoptosis
conformation
inducing
Prior art date
Application number
AT02760451T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Zdenek Richard Holan
Stephanie Reader
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE325341T1 publication Critical patent/ATE325341T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
AT02760451T 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden ATE325341T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31329001P 2001-08-17 2001-08-17

Publications (1)

Publication Number Publication Date
ATE325341T1 true ATE325341T1 (de) 2006-06-15

Family

ID=23215136

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02760451T ATE325341T1 (de) 2001-08-17 2002-08-19 Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden
AT02767738T ATE428781T1 (de) 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02767738T ATE428781T1 (de) 2001-08-17 2002-08-19 Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Country Status (14)

Country Link
US (5) US7199228B2 (de)
EP (2) EP1448986B1 (de)
JP (2) JP4504015B2 (de)
KR (2) KR100943567B1 (de)
AT (2) ATE325341T1 (de)
AU (2) AU2002330663B2 (de)
CA (2) CA2457783A1 (de)
DE (2) DE60211206T2 (de)
DK (1) DK1417307T3 (de)
ES (1) ES2325247T3 (de)
HK (1) HK1069205A1 (de)
IL (4) IL160407A0 (de)
MX (2) MXPA04001480A (de)
WO (2) WO2003016528A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
EP2363133A1 (de) * 2000-03-31 2011-09-07 Trustees of Boston University Zusammensetzung enhalted DNA-Fragmente und ihre medizinischen und kosmetischen Verwendungen
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
KR100943567B1 (ko) * 2001-08-17 2010-02-22 바이오니취 라이프 사이언시즈 인코포레이티드 세포사멸-유도성 포스포디에스테르올리고뉴클레오타이드의 입체구조-활성 관계성
WO2004014312A2 (en) * 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
JP2013510189A (ja) * 2009-11-10 2013-03-21 バイオニケ ライフ サイエンシーズ インコーポレイテッド 非ｄｎａ塩基含有ポリヌクレオチド組成物、および免疫応答の調節のためのそれらの使用
CN106709925A (zh) * 2016-12-30 2017-05-24 上海联影医疗科技有限公司 医学图像中椎块的定位方法及其装置
CN107704697B (zh) * 2017-10-18 2019-08-20 西南交通大学 一种型材三维拉弯成形性预测评价优化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106727A (en) * 1989-04-27 1992-04-21 Life Technologies, Inc. Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
WO1993018187A1 (en) * 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
DK0805876T3 (da) * 1995-01-19 2000-11-06 Gen Probe Inc Nukleinsyreamplifikationsoligonukleotider og prober til Lyme-sygdom-associeret Borrelia
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
JP2003517283A (ja) * 1999-04-08 2003-05-27 オアシス バイオサイエンシーズ インコーポレイティッド プライマーペアの増幅及び配列決定並びにそれらの使用
EP1238070B1 (de) * 1999-12-13 2007-08-15 Bioniche Life Sciences Inc. Synthetische oligonukleotide die therapeutisch nützlich sind
KR100943567B1 (ko) * 2001-08-17 2010-02-22 바이오니취 라이프 사이언시즈 인코포레이티드 세포사멸-유도성 포스포디에스테르올리고뉴클레오타이드의 입체구조-활성 관계성
EP1465910A4 (de) * 2002-02-20 2005-03-16 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung der genexpression von checkpointkinase-1 (chk-1) unter verwendung kurzer interferierender nukleinsäuren

Also Published As

Publication number Publication date
EP1417307A2 (de) 2004-05-12
WO2003016567A3 (en) 2004-06-03
HK1069205A1 (en) 2005-05-13
MXPA04001315A (es) 2004-05-20
JP2005521119A (ja) 2005-07-14
KR101017483B1 (ko) 2011-02-25
AU2002326067B2 (en) 2007-05-31
DE60231986D1 (de) 2009-05-28
US20030144233A1 (en) 2003-07-31
WO2003016567A2 (en) 2003-02-27
EP1417307B1 (de) 2009-04-15
US7199228B2 (en) 2007-04-03
JP4504015B2 (ja) 2010-07-14
IL160407A0 (en) 2004-07-25
MXPA04001480A (es) 2004-05-20
KR20040032925A (ko) 2004-04-17
JP2005509411A (ja) 2005-04-14
ATE428781T1 (de) 2009-05-15
US20030113763A1 (en) 2003-06-19
DE60211206T2 (de) 2006-10-26
JP4469603B2 (ja) 2010-05-26
KR20040030138A (ko) 2004-04-08
IL160408A (en) 2010-05-31
WO2003016528A3 (en) 2003-10-09
US7200531B2 (en) 2007-04-03
US20080077372A1 (en) 2008-03-27
US20110160291A1 (en) 2011-06-30
EP1448986A2 (de) 2004-08-25
ES2325247T3 (es) 2009-08-31
DK1417307T3 (da) 2009-07-13
CA2457783A1 (en) 2003-02-27
US7893242B2 (en) 2011-02-22
KR100943567B1 (ko) 2010-02-22
WO2003016528A2 (en) 2003-02-27
CA2457789A1 (en) 2003-02-27
AU2002330663B2 (en) 2007-09-20
US20080081793A1 (en) 2008-04-03
IL160408A0 (en) 2004-07-25
EP1448986B1 (de) 2006-05-03
US8350016B2 (en) 2013-01-08
DE60211206D1 (de) 2006-06-08
IL160407A (en) 2010-02-17

Similar Documents

Publication Publication Date Title
HK1069205A1 (en) Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
DE69233599T2 (de) Unterbrochene 2'-modifizierte Oligonukleotide
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
AR019011A1 (es) Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
BR9811805A (pt) Derivados quinazolina substituìda e seu uso como inibidores de quinase tirosina
BR0007663A (pt) Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
ATE253586T1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE505474T1 (de) Inhibitoren von nukleosidphosphorylasen und nukleosidasen
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DE602004014170D1 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
DK1045690T3 (da) Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
TR200200278T2 (tr) Kalsilitik bileşimler
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE10393716D2 (de) Decoy-Oligonukleotid-Hemmung der CD40-Expression
DE602004028497D1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof
ECSP003611A (es) Derivados de 3(5)-ureido- pirazol, procedimiento para su preparacion y su utilizacion como agentes antitumorales

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties